What's Going On With Cel-Sci Shares Premarket On Monday?
What's Going On With Cel-Sci Shares Premarket On Monday?
The company plans to use proceeds to support the development of Multikine, general corporate purposes, and working capital.Cel-Sci Corporation (AMEX:CVM) shares are trading lower premarket on Monday.
CEL-SCI公司（美交所：CVM）週一盤前股價下跌。
On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.
週日，該公司披露了公開發行1613萬股普通股或預先融資Warrants，每股價格爲0.31美元。
The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions.
該公司計劃募集約500萬的毛收益。此次發行預計將於2024年12月31日結束，需遵循慣例條件。
The company plans to use proceeds to support the development of Multikine, general corporate purposes, and working capital.
該公司計劃使用所得資金支持Multikine的開發、一般企業用途以及流動資金。
Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for head and neck cancer.
本月早些時候，CEL-SCI強調在其FDA批准的頭頸癌確認註冊研究中使用Multikine的強大生物學理由。
The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial.
該研究涉及212名新診斷的局部晚期可切除頭頸癌患者，重點關注那些在之前的第3期試驗中用Multikine展示出73%存活率的患者，而對照組患者的存活率爲45%。
Price Action: CVM shares are down 29.9% at $0.4204 premarket at the last check Monday.
價格動態：CVm股價在最後一次檢查時週一盤前下跌29.9%，至0.4204美元。
- US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking
- 美國股指期貨在週五下跌後小幅滑落：'聖誕老人反彈'是否有疑問？分析師稱這有點盈利回吐。
Photo via Shutterstock.
圖片來自Shutterstock。
